Efficacy and comparative analysis of consumer qualities of the Desmopressin intranasal drops in patients with central diabetes insipidus
https://doi.org/10.14341/omet2014331-36
Abstract
Objective: To evaluate the effectiveness and conduct a comparative analysis of consumer qualities of desmopressin intranasal drops 0.01% 5ml ("Biopharm", Georgia) in patients with central diabetes insipidus (CDI). Materials and Methods: The study included 9 patients (3 men and 6 women, mean age 44 ± 12 years) diagnosed with CDI. Patients for 7 days were switched to desmopressin intranasal drops 0.01% (JSC "Biopharm" Georgia) from there basal desmopressin preparations by means of recalculating daily dose by proposed formular: 10 mg (2 drops) of desmopressin intranasal drops = 0.2 mg of desmopressin tableted = 10 micrograms (one dose) of intranasal spray metered desmopressin = 120 mcg sublingual tablets of desmopressin. Safety biochemical parameters, efficiency to control of the main manifestations of CDI, increase in urine specific gravity, quality of life, basic consumer properties of different desmopressin preparation were evaluates at baseline and after treatment period. Results: Desmopressin nasal drops 0.01% showed to be an effective drug for the treatment of patients with CDI. Dose calculation algorithm daily was adequate in most patients. Hyponatremia was detected in 2 out of 9 patients during the study period but has been related to study drug alone in one case. The investigational drug was marked convenient to use by less than 25% of patients which may be associated with the pharmacological form of the drug as intranasal drops with special storage conditions (refrigerator). Conclusions: The drug desmopressin intranasal drops can be recommended as a second line (reserve) therapy in the treatment of patients CDI. Sodium levels should be checked during initiation of therapy.
About the Authors
Ekaterina Pigarova
Endocrinology Research Centre, Moscow
Russian Federation
MD, Ph.D., senior researcher at the Department of Neuroendocrinology and osteopathy
Russian Federation
MD, Ph.D., senior researcher at the Department of Neuroendocrinology and osteopathy
Larisa Dzeranova
Endocrinology Research Centre, Moscow
Russian Federation
MD, Ph.D., chief researcher at the Department of Neuroendocrinology and osteopathies
Russian Federation
MD, Ph.D., chief researcher at the Department of Neuroendocrinology and osteopathies
Lyudmila Rozhinskaya
Endocrinology Research Centre, Moscow
Russian Federation
MD, PhD., Head of the Department of Neuroendocrinology and osteopathies
Russian Federation
MD, PhD., Head of the Department of Neuroendocrinology and osteopathies
References
1. Дзеранова Л.К, Пигарова Е.А. Несахарный диабет. / Эндокринология: национальное руководство. Под ред. Дедов И.И, Мельниченко Г.А. – М.: ГЭОТАР-Медиа. 2008. – С. 673-677. [Dzeranova LK, Pigarova EA. Nesakharnyy diabet. In: Dedov II, Mel'nichenko GA, editor. Endokrinologiya: natsional'noe rukovodstvo. GEOTAR-Media, 2008. p. 673-677.]
2. Дзеранова Л.К., Пигарова Е.А. Центральный несахарный диабет: современные аспекты диагностики и лечения //Лечащий врач. – 2006. – Т. 10. – С. 42-47. [Dzeranova LK, Pigarova EA. Tsentral'nyy nesakharnyy diabet: sovremennye aspekty diagnostiki i lecheniya. Lechashchiy vrach 2006;10:42-47.]
3. Robertson GL. Disorders of Neurohypophysis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL , and Jameson JL, editors. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2001; 2052-2060.
4. Verbalis JG. Disorders of body water homeostasis. Best Practice & Research Clinical Endocrinology &; Metabolism 2003;17(4):471-503. doi: 10.1016/S1521-690X(03)00049-6.
5. Пигарова Е.А., Дзеранова Л.К., Рожинская Л.Я. Клинический случай центрального несахарного диабета, осложненного патологией центра жажды //Ожирение и метаболизм. – 2008. – №. 3. – С. 28-31. [Pigarova EA, Dzeranova LK, Rozhinskaya LY. Klinicheskiy sluchay tsentral'nogo nesakharnogo diabeta, oslozhnennogo patologiey tsentra zhazhdy. Obesity and metabolism. 2008;(3):42-45] doi: 10.14341/2071-8713-5337
6. Robertson GL. Dipsogenic diabetes insipidus: a newly recognized syndrome caused by a selective defect in the osmoregulation of thirst. Trans Assoc Am Physicians 1987;100:241-249. PMID: 3455068.
7. Дедов И. И., Пигарова Е. А., Рожинская Л. Я. Открытое проспективное клиническое исследование по оценке эффективности и безопасности применения десмопрессина в форме назального спрея у пациентов с центральным несахарным диабетом: фармакоэкономические аспекты //Лечащий врач. – 2010. – Т. 9. – С. 2-5. [Dedov II, Pigarova EA, Rozhinskaya LY. Otkrytoe prospektivnoe klinicheskoe issledovanie po otsenke effektivnosti i bezopasnosti primeneniya desmopressina v forme nazal'nogo spreya u patsientov s tsentral'nym nesakharnym diabetom. Lechashchiy vrach. 2010. 9:2-5.]
Review
For citations:
, , Efficacy and comparative analysis of consumer qualities of the Desmopressin intranasal drops in patients with central diabetes insipidus. Obesity and metabolism. 2014;11(3):31-36. (In Russ.) https://doi.org/10.14341/omet2014331-36
Views:
478
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
